DOCSLIB.ORG

CCND1 and CDKN1B Polymorphisms and Risk of Breast Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CCND1 and CDKN1B Polymorphisms and Risk of Breast Cancer ANTICANCER RESEARCH 30: 3093-3098 (2010) CCND1 and CDKN1B Polymorphisms and Risk of Breast Cancer EMEL CANBAY1, ILHAN YAYLIM ERALTAN2, ALI CERCEL3, TURGAY ISBIR2, ERTUGRUL GAZIOGLU3, FATIH AYDOGAN3, CANAN CACINA2, ALI CENGIZ3, MEHMET FERAHMAN3, EMEL ZENGIN4 and HILAL UNAL3 1General Surgery, Basaksehir State Hospital, Istanbul 34230, Turkey; 2Department of Molecular Medicine, Experimental Medicine and Research Institute (DETAE), Istanbul University, Istanbul, 34100, Turkey; Departments of 3General Surgery and 4Biochemistry, Cerrahpasa Medical School, Istanbul University, Istanbul, 34098, Turkey Abstract. Background and Objectives. Previous studies have Breast cancer includes a heterogeneous group of tumours shown alterations in the cell cycle regulatory proteins in breast with variable prognosis and is the second leading cause of carcinomas. However, the results of these studies remain cancer related death among women (1). The genetic material controversial. Cyclin D1 (CCND1) and p27KIP1 (CDKN1B) which modifies the expression of proteins in cell cycle are two essential regulators of cell cycle progression. This progression is altered in tumourigenesis (2). The cell cycle study aimed to investigate the associations of CCND1 A870G is promoted by activation of cyclin dependent kinases, which and CDKN1B C79T polymorphisms with breast cancer risk. are positively regulated by cyclins and negatively by cyclin Patients and Methods. Polymerase chain reaction-restriction dependent kinase inhibitors. fragment length polymorphism (PCR-RFLP) was used to Cyclin D1 (CCND1), a member of the D-type cyclin determine the genotype and allelic frequencies of family (3), is the main cyclin that regulates the G1/S phase polymorphisms. Seventy-eight breast cancer patients and 84 progression. It does this by phosphorylating and inactivating age-matched healthy controls were included in the study. the RB protein by coupling with cyclin-dependent kinase 4 Results. Frequencies of CT genotype and T allele of CDKN1B (CDK4), which may induce the release of the transcription were found to be higher in breast cancer patients than in factor E2F from the RB protein and start the function of DNA controls (p=0.013, OR: 1.514 95% CI: 1.086-2.114.15; synthesis (4). However, cyclin D1 overexpression may result p=0.007, OR=1.496; 95% CI: 1.111-2.014, respectively). The in the phosphorylation of RB protein, in advance, frequency of AA genotype of CCND1 was decreased in uncontrolled cell growth, and the development of cancer (4). hormone receptor- (estrogen and progesterone receptors) It has been indicated that the CCND1 gene is amplified in up negative patients with breast cancer (p<0.049, OR=0.286; to 20% of breast cancer cases and overexpressed in more than 95% CI: 0.071-1.142) Conclusions. Even though CDKN1B 50% of mammary tumours (5), and this appears to be an early polymorphism appears to be an important predictive factor for event in breast cancer formation (6). In exon 4, CCND1 there breast cancer risk and CCND1 polymorphism may be a is a silent G to A substitution at nt870 (rs603965). Betticher prognostic biomarker for breast cancer, further investigations et al. (7) demonstrated that CCND1 G870A produces an with larger study groups are needed to fully elucidate the role alternative protein, transcript-b, which has been suggested to of CCND1 and CDKN1B polymorphisms in the development have a longer half-life than transcript-a (7, 8). Several studies and prognosis of breast cancer. also reported that transcript-b was a poor catalyst of RB phosphorylation or inactivation and markedly enhanced cell transformation activity compared to transcript-a (9, 10). A single nucleotide adenine-to-guanine substitution (A870G) in exon 4 of the CCND1 gene is a common Correspondence to: Emel Canbay MD, Ph.D, Atakoy 11.kisim polymorphism and is known to influence the splicing at the Gelincik Apt. B Blok Daire 12 Istanbul, 34158,Turkey. Tel: +212 6619290, Fax:+212 4880180, email: [email protected] exon 4-intron 4 boundary resulting in an alternate transcript (transcript-b) (7-9). This alternate transcript produced by the Key Words: Cyclin D polymorphism, CDKN1B polymorphism, 870A allele lacks exon 5 of CCND1 and contains a PEST- breast cancer, Turkish population rich region that is postulated to target proteins for rapid 0250-7005/2010 $2.00+.40 3093 ANTICANCER RESEARCH 30: 3093-3098 (2010) Table I. PCR and RFLP procedures and expected products of CCND1 (A870G) and CDKN1B (C79T) genes. Primers (forward and reverse) PCR PCR Restriction Restriction conditions product enzyme products CCND1 5’GTGAAG TTCATTTCCAATCCGC-3 25 μl of PCR 167 NciI A/A: 167 (23)* 5’GGGACATCACCCTCACTTAC-3’ mixture: A/G: 167, 145 16 mM of each dNTP, G/G: 145 100 pmol/μl of each primer, 15 mM of MgCl2, 1 U Taq polymerase ’ 35 cycles: 94˚C 45 s, 55˚C 45 s, 72˚C 45 s CDKN1B 5’ TGGCTCGTCGGGGTCT 3 ‘ 25 μl of PCR 195 HaeIII C/C: 129 (20) * 5’ CCATCCGCTCCAGGCT 3’ mixture: C/T: 129, 66 200 mM dNTP, T/T: 195 100 pmol/μl of each primer, 15 mM of MgCl2 1U Taq polymerase 35 cycles: 94˚C 30 sec, 56˚C 45 sec, 72˚ C 45 sec degradation, and which is hypothesized to be more stable concentrations, they have been shown to improve compared to the product of the 870G allele. It has been complexing between CDK4/6 and cyclin D, but still inhibit shown that transcript-b leads to a longer half-life of CCND1, CDK2–Cyclin-E (19). Loss of CDKN1B expression is also which may bypass the G1/S-checkpoint (7). a common event in breast cancer, and has been strongly Several molecular epidemiological studies have been associated with high tumour grade and poor prognosis (20). conducted to examine the association between CCND1 The V109G polymorphism of the p27 gene, CDKN1B, G870A polymorphism and breast cancer risk (11-17), but the examined by polymerase chain reaction analysis of tumour results remain inconsistent. specimens, was associated with shortened disease-free Progression through the cell cycle is governed by the survival in a subset of patients with infiltrating metastasis- activation of cyclin-dependent kinases (CDKs), and free breast cancer (19). However, association of the CDKN1B sequential activation of CDK–cyclin complexes leads to the C79T polymorphism and breast cancer risk has been phosphorylation and inactivation of RB, allowing analysed previously only in two studies (21, 22). transcription of cell cycle genes by the E2F family of The aim of this study was to investigate the possible transcription factors (18). This process is kept in check by correlation between the polymorphisms of CCND1 G870A inhibitors (CKIs). These are referred to by various names, and CDKN1B C79T and development of breast cancer. but are generally classified into two groups: inhibitors of kinase 4 (INK4) and CDK inhibitory protein/kinase inhibitor Patients and Methods protein (CIP/KIP). The INK4 groups includes CDKN2A (INK4A/p16 and ARF/p14), CDKN2B (INK4B/p15), Study population. The patient group consisted of 78 consecutive CDKN2C (INK4C/p18) and CDKN2D (INK4D/p19). These breast cancer patients with median age 52.5 ( range 30-79) years, bind to both CDK4 and CDK6 to prevent their association who were admitted to Istanbul University Cerrahpasa Medical Faculty, Department of General Surgery, Breast Services. The with cyclin D. The CIP/KIP group comprises CDKN1A control group consisted of age- and sex-matched healthy subjects. (WAF1/p21/CIP1) and CDKN1B (KIP1/p27), which form The control subjects were randomly selected among volunteer blood heterotrimeric complexes with the G1 to S transition CDKs. donors. Subjects with a personal or family history of any cancer and The CIP/KIP proteins do not affect cyclin binding. At low chronic diseases such as cardiovascular or cerebrovascular disease, 3094 Canbay et al: CCND1 and CDKN1B in Breast Cancer diabetes mellitus, hypertension, or renal disease were excluded from Table II. Characteristics of patients with breast cancer. the study. Control subjects were not taking any regular medication at time of the study. Eighty-four healthy women, presenting a Parameters Patients (n=78) Controls (n=84) median age 46 (range 30-81) years, were used as a control group. Informed consent was obtained from all participants. Breast cancer n%n% patients had previously undergone appropriate surgery. Questionnaires, medical records, and pathological reports were used Age (years) to confirm the diagnosis and cancer status. This study protocol was <40 22 28.2 31 36.9 approved by the Local Ethical Committee at Istanbul University ≥40 56 71.8 53 63.1 Smoking status Cerrahpasa Medical School. Yes 15 20.7 22 38.1 No 59 79.3 72 61.2 Polymorphism Analysis. This study was carried out in the Alcohol consumption Department of Molecular Medicine, Istanbul University Yes 1 1.4 2 2.4 Experimental Medicine and Research Institute. Genomic DNA No 73 98.6 82 97.6 was extracted from peripheral whole blood containing EDTA Family history according to the salting-out technique (23). Genotyping was Yes 5 6.8 performed by polymerase chain reaction (PCR) and restriction No 69 93.2 fragment length polymorphism (RFLP), the procedures of which Histopathology are given in Table I (22, 23). The appropriate primers were used Ductal 67 85.7 to amplify the corresponding gene of the subjects by PCR. The Lobular 6 7.8 reaction products were digested by using the appropriate enzyme Mixed 4 5.2 at 37˚C. The digested products were analysed on 3% agarose gel Other 1 1.3 stained with ethidium bromide and examined under Tumour stage transillumination. Each gel was read by two observers unaware T1 19 24.3 of the subject’s status. If there was any conflict, samples were T2 53 67.9 repeated. The expected results after restriction for each gene are T3 3 3.9 also given in Table I.
Load more

Recommended publications
  • Cyclin D1/Cyclin-Dependent Kinase 4 Interacts with Filamin a and Affects the Migration and Invasion Potential of Breast Cancer Cells
    Published OnlineFirst February 28, 2010; DOI: 10.1158/0008-5472.CAN-08-1108 Tumor and Stem Cell Biology Cancer Research Cyclin D1/Cyclin-Dependent Kinase 4 Interacts with Filamin A and Affects the Migration and Invasion Potential of Breast Cancer Cells Zhijiu Zhong, Wen-Shuz Yeow, Chunhua Zou, Richard Wassell, Chenguang Wang, Richard G. Pestell, Judy N. Quong, and Andrew A. Quong Abstract Cyclin D1 belongs to a family of proteins that regulate progression through the G1-S phase of the cell cycle by binding to cyclin-dependent kinase (cdk)-4 to phosphorylate the retinoblastoma protein and release E2F transcription factors for progression through cell cycle. Several cancers, including breast, colon, and prostate, overexpress the cyclin D1 gene. However, the correlation of cyclin D1 overexpression with E2F target gene regulation or of cdk-dependent cyclin D1 activity with tumor development has not been identified. This suggests that the role of cyclin D1 in oncogenesis may be independent of its function as a cell cycle regulator. One such function is the role of cyclin D1 in cell adhesion and motility. Filamin A (FLNa), a member of the actin-binding filamin protein family, regulates signaling events involved in cell motility and invasion. FLNa has also been associated with a variety of cancers including lung cancer, prostate cancer, melanoma, human bladder cancer, and neuroblastoma. We hypothesized that elevated cyclin D1 facilitates motility in the invasive MDA-MB-231 breast cancer cell line. We show that MDA-MB-231 motility is affected by disturbing cyclin D1 levels or cyclin D1-cdk4/6 kinase activity.
    [Show full text]
  • Role for Cyclin D1 in UVC-Induced and P53-Mediated Apoptosis
    Cell Death and Differentiation (1999) 6, 565 ± 569 ã 1999 Stockton Press All rights reserved 13509047/99 $12.00 http://www.stockton-press.co.uk/cdd Role for cyclin D1 in UVC-induced and p53-mediated apoptosis Hirofumi Hiyama1 and Steven A. Reeves*,1 irradiation of human fibroblasts is mediated by the p53- induced cyclin/cdk inhibitor, p21.3 Cell cycle progression 1 Molecular Neuro-Oncology, Neuroscience Center, Neurosurgical Services, through the G1/S boundary is controlled by G1 cyclins, Massachusetts General Hospital and Harvard Medical School, Boston, including D and E type cyclins and their cyclin-dependent Massachusetts 02129, USA kinases (cdk), whose phosphorylation of the retinoblastoma * corresponding author: Steven A. Reeves, Molecular Neuro-Oncology, gene product (pRB) causes a dissociation of the pRB and Neuroscience Center, Massachusetts General Hospital, 149 13th Street, Charlestown, MA 02129, USA. tel.: (617) 726-5510; fax: (617) 726-5079; E2F-1 interaction, and subsequent activation of E2F- e-mail: [email protected] mediated transcription. As an universal inhibitor of cdks, p21 can inhibit phosphorylation of pRB and allow for G1 arrest.4 Recent studies have shown that overexpression of cyclin Received 13.10.98; revised 19.03.99; accepted 23.03.99 D1 in serum-starved cell types can induce apoptosis.5 Edited by T. Cotter Interestingly, the induction of the cell death program was found to be associated with an increase in cyclin D1- dependent kinase activity.6 Moreover, in cells that contain Abstract wild-type p53, the overexpression of E2F-1 leads to S- 7 DNA damaging agents such as ultraviolet (UV) induce cell phase entry and p53-dependent apoptosis.
    [Show full text]
  • Expression Profiling of KLF4
    Expression Profiling of KLF4 AJCR0000006 Supplemental Data Figure S1. Snapshot of enriched gene sets identified by GSEA in Klf4-null MEFs. Figure S2. Snapshot of enriched gene sets identified by GSEA in wild type MEFs. 98 Am J Cancer Res 2011;1(1):85-97 Table S1: Functional Annotation Clustering of Genes Up-Regulated in Klf4 -Null MEFs ILLUMINA_ID Gene Symbol Gene Name (Description) P -value Fold-Change Cell Cycle 8.00E-03 ILMN_1217331 Mcm6 MINICHROMOSOME MAINTENANCE DEFICIENT 6 40.36 ILMN_2723931 E2f6 E2F TRANSCRIPTION FACTOR 6 26.8 ILMN_2724570 Mapk12 MITOGEN-ACTIVATED PROTEIN KINASE 12 22.19 ILMN_1218470 Cdk2 CYCLIN-DEPENDENT KINASE 2 9.32 ILMN_1234909 Tipin TIMELESS INTERACTING PROTEIN 5.3 ILMN_1212692 Mapk13 SAPK/ERK/KINASE 4 4.96 ILMN_2666690 Cul7 CULLIN 7 2.23 ILMN_2681776 Mapk6 MITOGEN ACTIVATED PROTEIN KINASE 4 2.11 ILMN_2652909 Ddit3 DNA-DAMAGE INDUCIBLE TRANSCRIPT 3 2.07 ILMN_2742152 Gadd45a GROWTH ARREST AND DNA-DAMAGE-INDUCIBLE 45 ALPHA 1.92 ILMN_1212787 Pttg1 PITUITARY TUMOR-TRANSFORMING 1 1.8 ILMN_1216721 Cdk5 CYCLIN-DEPENDENT KINASE 5 1.78 ILMN_1227009 Gas2l1 GROWTH ARREST-SPECIFIC 2 LIKE 1 1.74 ILMN_2663009 Rassf5 RAS ASSOCIATION (RALGDS/AF-6) DOMAIN FAMILY 5 1.64 ILMN_1220454 Anapc13 ANAPHASE PROMOTING COMPLEX SUBUNIT 13 1.61 ILMN_1216213 Incenp INNER CENTROMERE PROTEIN 1.56 ILMN_1256301 Rcc2 REGULATOR OF CHROMOSOME CONDENSATION 2 1.53 Extracellular Matrix 5.80E-06 ILMN_2735184 Col18a1 PROCOLLAGEN, TYPE XVIII, ALPHA 1 51.5 ILMN_1223997 Crtap CARTILAGE ASSOCIATED PROTEIN 32.74 ILMN_2753809 Mmp3 MATRIX METALLOPEPTIDASE
    [Show full text]
  • Cyclin D1 Amplification Is Independent of P16 Inactivation in Head And
    Oncogene (1999) 18, 3541 ± 3545 ã 1999 Stockton Press All rights reserved 0950 ± 9232/99 $12.00 http://www.stockton-press.co.uk/onc Cyclin D1 ampli®cation is independent of p16 inactivation in head and neck squamous cell carcinoma K Okami1,3, AL Reed1, P Cairns1, WM Koch1, WH Westra2, S Wehage1, J Jen1 and D Sidransky*,1 1Department of OtolaryngologyÐHead & Neck Surgery, Division of Head and Neck Cancer Research, Johns Hopkins University School of Medicine, 818 Ross Research Building, 720 Rutland Avenue, Baltimore, Maryland, MD 21205-2196, USA; 2Department of Pathology, 7181 Meyer Building, Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, Maryland, MD 21287, USA; 3Department of Otolaryngology, Yamaguchi University, Ube 755, Japan Progression through the G1 phase of the cell cycle is kinase (cdk) 4 complexes. This cdk4 phosphorylation mediated by phosphorylation of the retinoblastoma activity is negatively regulated by the tumor suppressor protein (pRb) resulting in the release of essential gene p16 (a CDK inhibitor), and positively by cyclin transcription factors such as E2F-1. The phosphorylation D1. Each individual component of this p16-cyclin D1- of pRb is regulated positively by cyclin D1/CDK4 and Rb pathway is commonly targeted in various malig- negatively by CDK inhibitors, such as p16 (CDKN2/ nancies (Weinberg, 1995; Sherr, 1996). We previously MTS-1/INK4A). The p16 /cyclin D1/Rb pathway plays reported a high frequency (83%) of p16 inactivation in a critical role in tumorigenesis and many tumor types human HNSCC (Reed et al., 1996) and less frequent display a high frequency of inactivation of at least one inactivation (13%) of pRb (Yoo et al., 1994).
    [Show full text]
  • Immunohistochemical Evaluation of P63 and Cyclin D1 in Oral Squamous Cell Carcinoma and Leukoplakia
    https://doi.org/10.5125/jkaoms.2017.43.5.324 ORIGINAL ARTICLE pISSN 2234-7550·eISSN 2234-5930 Immunohistochemical evaluation of p63 and cyclin D1 in oral squamous cell carcinoma and leukoplakia Sunit B. Patel1, Bhari S. Manjunatha2, Vandana Shah3, Nishit Soni4, Rakesh Sutariya5 1Department of Oral Pathology, Ahmedabad Dental College, Ahmedabad, India, 2Department of Oral Biology, Basic Dental Sciences, Faculty of Dentistry, Al-Huwaiyah, Taif University, Taif, Kingdom of Saudi Arabia, 3Department of Oral Pathology, K.M.Shah Dental College, Vadodara, 4Department of Oral Pathology, Karnavati School of Dentistry, Gandhinagar, 5Department of Oral Pathology, Vaidik Dental College, Daman, India Abstract (J Korean Assoc Oral Maxillofac Surg 2017;43:324-330) Objectives: There are only a limited number of studies on cyclin D1 and p63 expression in oral squamous cell carcinoma (OSCC) and leukoplakia. This study compared cyclin D1 and p63 expression in leukoplakia and OSCC to investigate the possible correlation of both markers with grade of dys- plasia and histological grade of OSCC. Materials and Methods: The study included a total of 60 cases, of which 30 were diagnosed with OSCC and 30 with leukoplakia, that were evalu- ated immunohistochemically for p63 and cyclin D1 expression. Protein expression was correlated based on grades of dysplasia and OSCC. Results: Out of 30 cases of OSCC, 23 cases (76.7%) were cyclin D1 positive and 30 cases (100%) were p63 positive. Out of 30 cases of leukoplakia, 21 cases (70.0%) were cyclin D1 positive and 30 (100%) were p63 positive (P<0.05). Conclusion: The overall expression of cyclin D1 and p63 correlated with tumor differentiation, and increases were correlated with poor histological grades, from well-differentiated to poorly-differentiated SCC.
    [Show full text]
  • Charles M. Perou, Phd Associate Professor Departments of Genetics
    Charles M. Perou, PhD Associate Professor Departments of Genetics and Pathology Carolina Center for Genome Sciences Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Identification of GBM Subtypes using Gene Expression Profiling Agilent Custom Affymetrix Human Affymetrix HT-HG- 244k Exon 1.0 Array U133A Array Microarray Identify Samples and Genes represented on all 3 platforms Factor Analysis Single unified gene expression measurement for each gene 202 patients 11,681 genes Identification of GBM Subtypes Census Clustering of the 202 samples X 1740 Unsupervised clustering of 1740 genes suggests that 4 subtypes of GBM exist variably expressed genes selected using a unified gene expression measure across 3 expression platforms Core TCGA Samples (173) Gene Ontology/Pathway: with Subtype-defining genes • ProNeural: 1. nervous system development ProNeural Normal-like EGFR Mesenchymal 2. neuron differentiation (SOXs) 3. cell cycle = proliferation 4. cell adhesion molecules 5. ErbB signaling pathway FBXO3 GABRB2 • Normal‐like: SNCG NTSR2 1. nucleotide metabolic process MBP 2. neurological system process DLL3 3. axon NKX2-2, NRXN1, NRXN2 TOP2B, CDC7, MYB 4. neuron projection SOX2, SOX4, SOX10,SOX11 5. synaptic transmission ERBB3, PAK3, PAK7 NCAM1 OLIG2 • EGFR: 1. regulation of transcription 2. cell migration 3. nervous system development FGFR3 4. cell proliferation PDGFRA 5. metal ion binding EGFR AKT2 GLI2 TGFB3 • Mesenchymal: CASP8, CASP5, CASP4, CASP1 1. immune response COL8A2, COL5A1, COL1A1,COL1A2 2. receptor activity ILR4 CHI3L1 3. wound healing TRADD TLR2, TLR4, 4. cytokine and chemokine IGFBI mediated signaling pathway RELB 5. NF‐B Signaling Pathway Correlations between gene expression subtypes and clinical parameters Survival Analysis of Subtypes n=196 Subtypes are correlated with: 1.
    [Show full text]
  • Supplemental Table S1 (A): Microarray Datasets Characteristics
    Supplemental table S1 (A): Microarray datasets characteristics Title Summary Samples Literature ref. GEO ref. Acquisition of granule Gene expression profiling of 27 (1) GSE 11859 neuron precursor identity cerebellar tumors generated and Hedgehog‐induced from various early and late medulloblastoma in mice. stage CNS progenitor cells Medulloblastomas derived Study of mouse 5 (2) GSE 7212 from Cxcr6 mutant mice medulloblastoma in response respond to treatment with to inhibitor of Smoothened a Smoothened inhibitor Expression profiles of Identification of distinct classes 10 (3) GSE 9299 mouse medulloblastoma of up‐regulated or down‐ 339 & 340 regulated genes during Hh dependent tumorigenesis Genetic alterations in Identification of differently 10 (4) GSE 6463 mouse medulloblastomas expressed genes among CGNPs 339 & and generation of tumors and CGNPs transfected with 340 from cerebellar granule retroviruses that express nmyc neuron precursors or cyclin‐d1 Patched heterozygous Analysis of granule cell 14 (5) GSE 2426 model of medulloblastoma precursors, pre‐neoplastic cells, GDS1110 and tumor cells 1. Schuller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG, et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh‐induced medulloblastoma. Cancer Cell 2008;14:123‐134. 2. Sasai K, Romer JT, Kimura H, Eberhart DE, Rice DS, Curran T. Medulloblastomas derived from Cxcr6 mutant mice respond to treatment with a smoothened inhibitor. Cancer Res 2007;67:3871‐3877. 3. Mao J, Ligon KL, Rakhlin EY, Thayer SP, Bronson RT, Rowitch D, et al. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res 2006;66:10171‐10178.
    [Show full text]
  • The P16 Status of Tumor Cell Lines Identifies Small Molecule Inhibitors Specific for Cyclin-Dependent Kinase 41
    Vol. 5, 4279–4286, December 1999 Clinical Cancer Research 4279 The p16 Status of Tumor Cell Lines Identifies Small Molecule Inhibitors Specific for Cyclin-dependent Kinase 41 Akihito Kubo,2 Kazuhiko Nakagawa,2, 3 CDK4 kinase inhibitors that may selectively induce growth Ravi K. Varma, Nicholas K. Conrad, inhibition of p16-altered tumors. Jin Quan Cheng, Wen-Ching Lee, INTRODUCTION Joseph R. Testa, Bruce E. Johnson, INK4A 4 The p16 gene (also known as CDKN2A) encodes p16 , Frederic J. Kaye, and Michael J. Kelley which inhibits the CDK45:cyclin D and CDK6:cyclin D com- Medicine Branch [A. K., K. N., N. K. C., F. J. K., B. E. J.] and plexes (1). These complexes mediate phosphorylation of the Rb Developmental Therapeutics Program [R. K. V.], National Cancer Institute, Bethesda, Maryland 20889; Department of Medical protein and allow cell cycle progression beyond the G1-S-phase Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania checkpoint (2). Alterations of p16 have been described in a wide 19111 [J. Q. C., W-C. L., J. R. T.]; and Department of Medicine, variety of histological types of human cancers including astro- Duke University Medical Center, Durham, North Carolina 27710 cytoma, melanoma, leukemia, breast cancer, head and neck [M. J. K.] squamous cell carcinoma, malignant mesothelioma, and lung cancer. Alterations of p16 can occur through homozygous de- ABSTRACT letion, point mutation, and transcriptional suppression associ- ated with hypermethylation in cancer cell lines and primary Loss of p16 functional activity leading to disruption of tumors (reviewed in Refs. 3–5). the p16/cyclin-dependent kinase (CDK) 4:cyclin D/retino- Whereas the Rb gene is inactivated in a narrow range of blastoma pathway is the most common event in human tumor cells, the pattern of mutational inactivation of Rb is tumorigenesis, suggesting that compounds with CDK4 ki- inversely correlated with p16 alterations (6–8), suggesting that nase inhibitory activity may be useful to regulate cancer cell a single defect in the p16/CDK4:cyclin D/Rb pathway is suffi- growth.
    [Show full text]
  • Tagging Single Nucleotide Polymorphisms in Cell Cycle Control Genes and Susceptibility to Invasive Epithelial Ovarian Cancer
    Research Article Tagging Single Nucleotide Polymorphisms in Cell Cycle Control Genes and Susceptibility to Invasive Epithelial Ovarian Cancer Simon A. Gayther,1 Honglin Song,2 Susan J. Ramus,1 Susan Kru¨ger Kjaer,4 Alice S. Whittemore,5 Lydia Quaye,1 Jonathan Tyrer,2 Danielle Shadforth,2 Estrid Hogdall,4 Claus Hogdall,6 Jan Blaeker,7 Richard DiCioccio,8 Valerie McGuire,5 Penelope M. Webb,9 Jonathan Beesley,9 Adele C. Green,9 David C. Whiteman,9 The Australian Ovarian Cancer Study Group,9 The Australian Cancer Study (Ovarian Cancer),20 Marc T. Goodman,10 Galina Lurie,10 Michael E. Carney,10 Francesmary Modugno,10 Roberta B. Ness,11 Robert P. Edwards,12 Kirsten B. Moysich,7 Ellen L. Goode,13 Fergus J. Couch,13 Julie M. Cunningham,13 Thomas A. Sellers,14 Anna H. Wu,15 Malcolm C. Pike,15 Edwin S. Iversen,16 Jeffrey R. Marks,16 Montserrat Garcia-Closas,17 Louise Brinton,17 Jolanta Lissowska,18 Beata Peplonska,19 Douglas F. Easton,3 Ian Jacobs,1 Bruce A.J. Ponder,2 Joellen Schildkraut,16 C. Leigh Pearce,15 Georgia Chenevix-Trench,9 Andrew Berchuck,16 Paul D.P. Pharoah,2 and on behalf of the Ovarian Cancer Association Consortium 1Translational Research Laboratories, University College London, London, United Kingdom; 2Cancer Research United Kingdom Department of Oncology and 3Cancer Research United Kingdom Genetic Epidemiology Unit, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom; 4Danish Cancer Society, Copenhagen, Denmark; 5Stanford University School of Medicine, Stanford, California; 6University of Copenhagen,
    [Show full text]
  • Screening for Differentially Expressed Genes Between Left‑And Right‑Sided
    ONCOLOGY LETTERS 6: 353-358, 2013 Screening for differentially expressed genes between left‑ and right‑sided colon carcinoma by microarray analysis HONG ZHU1, TIAN-CONG WU1, WEI-QIONG CHEN1, LI-JUN ZHOU1, YUE WU1, LIANG ZENG2 and HAI-PING PEI3 1Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008; 2Department of Pathology, Hunan Tumor Hospital, Changsha, Hunan 410013; 3Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China Received December 25, 2012; Accepted May 14, 2013 DOI: 10.3892/ol.2013.1414 Abstract. Left-sided colon carcinoma (LSCC) and right-sided and RSCC. These insights may therefore serve as a basis for colon carcinoma (RSCC) differ in their genetic susceptibili- the identification of novel colon cancer markers and thera- ties to neoplastic transformation. The present study identified peutic targets. 11 genes that were differentially expressed in LSCC and RSCC by expression profiling with microarray analysis. Compared Introduction with RSCC, the human genes for L-lactate dehydrogenase B chain (LDHB), cyclin-dependent kinase 4 inhibitor D Colon cancer is a significant cause of cancer‑related morbidity (CDKN2D), phosphatidylinositol-4-phosphate-3-kinase C2 and mortality, and is the third most fatal malignancy domain-containing subunit α (PI3KC2α), protocadherin fat 1 worldwide (1). In China and other economically developing (FAT; a human protein that closely resembles the Drosophila countries, colon cancer incidence rates have increased over tumor suppressor, fat) and dual specificity protein phospha- the past 20 years; most likely due to changes in the envi- tase 2 (DUSP2) were upregulated in LSCC. By contrast, ronment, individual lifestyle and nutritional habits (2).
    [Show full text]
  • CDKN2C-Null Leiomyosarcoma: a Novel
    original reports CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/ RB1–Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion Erik A. Williams, MD1; Radwa Sharaf, PhD1; Brennan Decker, MD, PhD2; Adrienne J. Werth, MD3; Helen Toma, MD3; Meagan Montesion, PhD1; Ethan S. Sokol, PhD1; Dean C. Pavlick, BS1; Nikunj Shah, BS1; Kevin Jon Williams, MD4; Jeffrey M. Venstrom, MD1; Brian M. Alexander, MD, MPH1; Jeffrey S. Ross, MD1,5; Lee A. Albacker, PhD1; Douglas I. Lin, MD, PhD1; Shakti H. Ramkissoon, MD, PhD1,6; and Julia A. Elvin, MD, PhD1 abstract PURPOSE Leiomyosarcoma (LMS) harbors frequent mutations in TP53 and RB1 but few actionable genomic alterations. Here, we searched for recurrent actionable genomic alterations in LMS that occur in the absence of common untreatable oncogenic drivers. METHODS Tissues from 276,645 unique advanced cancers, including 2,570 uterine and soft tissue LMS, were sequenced by hybrid-capture–based next-generation DNA and RNA sequencing/comprehensive genomic profiling of up to 406 genes. We characterized clinicopathologic features of relevant patient cases. RESULTS Overall, 77 LMS exhibited homozygous copy loss of CDKN2C at chromosome 1p32.3 (3.0% of LMS). Genomic alterations (GAs) in TP53, RB1, and ATRX were rare compared with the remainder of the LMS cohort (11.7% v 73.4%, 0% v 54.5%, 2.6% v 24.5%, respectively; all P , .0001). CDKN2C-null LMS patient cases were significantly enriched for GAs in CIC (40.3% v 1.4%) at 19q13.2, CDKN2A (46.8% v 7.0%), and RAD51B (16.9% v 1.7%; all P , .0001).
    [Show full text]
  • Increased Expression of Unmethylated CDKN2D by 5-Aza-2'-Deoxycytidine in Human Lung Cancer Cells
    Oncogene (2001) 20, 7787 ± 7796 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells Wei-Guo Zhu1, Zunyan Dai2,3, Haiming Ding1, Kanur Srinivasan1, Julia Hall3, Wenrui Duan1, Miguel A Villalona-Calero1, Christoph Plass3 and Gregory A Otterson*,1 1Division of Hematology/Oncology, Department of Internal Medicine, The Ohio State University-Comprehensive Cancer Center, Columbus, Ohio, OH 43210, USA; 2Department of Pathology, The Ohio State University-Comprehensive Cancer Center, Columbus, Ohio, OH 43210, USA; 3Division of Human Cancer Genetics, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University-Comprehensive Cancer Center, Columbus, Ohio, OH 43210, USA DNA hypermethylation of CpG islands in the promoter Introduction region of genes is associated with transcriptional silencing. Treatment with hypo-methylating agents can Methylation of cytosine residues in CpG sequences is a lead to expression of these silenced genes. However, DNA modi®cation that plays a role in normal whether inhibition of DNA methylation in¯uences the mammalian development (Costello and Plass, 2001; expression of unmethylated genes has not been exten- Li et al., 1992), imprinting (Li et al., 1993) and X sively studied. We analysed the methylation status of chromosome inactivation (Pfeifer et al., 1990). To date, CDKN2A and CDKN2D in human lung cancer cell lines four mammalian DNA methyltransferases (DNMT) and demonstrated that the CDKN2A CpG island is have been identi®ed (Bird and Wole, 1999). Disrup- methylated, whereas CDKN2D is unmethylated. Treat- tion of the balance in methylated DNA is a common ment of cells with 5-aza-2'-deoxycytidine (5-Aza-CdR), alteration in cancer (Costello et al., 2000; Costello and an inhibitor of DNA methyltransferase 1, induced a dose Plass, 2001; Issa et al., 1993; Robertson et al., 1999).
    [Show full text]